Exposure to Long Chain Polyunsaturated Fatty Acids Triggers Rapid Multimerization of Synucleins*

Detergent-stable multimers of α-synuclein have been found specifically in the brains of patients with Parkinson's disease and other neurodegenerative diseases. Here we show that recombinant α-synuclein forms multimers in vitro upon exposure to vesicles containing certain polyunsaturated fatty acid (PUFA) acyl groups, including arachidonoyl and docosahexaenoyl. This process occurs at physiological concentrations and much faster than in aqueous solution. PUFA-induced aggregation involves physical association with the vesicle surface via the large apolipoprotein-like lipid-binding domain that constitutes the majority of the protein. β- and γ-synucleins, as well as the Parkinson's disease-associated α-synuclein variants A30P and A53T, show similar tendencies to multimerize in the presence of PUFAs. Multimerization does not require the presence of any tyrosine residues in the sequence. The membrane-based interaction of the synucleins with specific long chain polyunsaturated phospholipids may be relevant to the protein family's physiological functions and may also contribute to the aggregation of α-synuclein observed in neurodegenerative disease.

[1]  Nobutaka Hattori,et al.  Ubiquitination of a New Form of α-Synuclein by Parkin from Human Brain: Implications for Parkinson's Disease , 2001, Science.

[2]  Eliot A. Brenowitz,et al.  Testosterone regulates α-synuclein mRNA in the avian song system , 2001 .

[3]  D. Eliezer,et al.  Conformational properties of alpha-synuclein in its free and lipid-associated states. , 2001, Journal of molecular biology.

[4]  S. Harvey,et al.  Insights into a plasma membrane signature. , 2001, Physiological genomics.

[5]  M. Behari,et al.  Mutations in the α‐synuclein gene in Parkinson's disease among Indians , 2001 .

[6]  J Q Trojanowski,et al.  Synucleinopathies: clinical and pathological implications. , 2001, Archives of neurology.

[7]  M. Goedert,et al.  The α‐Synucleinopathies: Parkinson's Disease, Dementia with Lewy Bodies, and Multiple System Atrophy , 2000 .

[8]  J. Trojanowski,et al.  Oxidative damage linked to neurodegeneration by selective alpha-synuclein nitration in synucleinopathy lesions. , 2000, Science.

[9]  R. Perrin,et al.  Interaction of human alpha-Synuclein and Parkinson's disease variants with phospholipids. Structural analysis using site-directed mutagenesis. , 2000, The Journal of biological chemistry.

[10]  J. Mallet,et al.  Rat α‐Synuclein Interacts with Tat Binding Protein 1, a Component of the 26S Proteasomal Complex , 2000 .

[11]  E. Kremmer,et al.  α-Synuclein accumulation in a case of neurodegeneration with brain iron accumulation type 1 (NBIA-1, formerly Hallervorden-Spatz syndrome) with widespread cortical and brainstem-type Lewy bodies , 2000, Acta Neuropathologica.

[12]  J. Trojanowski,et al.  Neurodegeneration with Brain Iron Accumulation, Type 1 Is Characterized by α-, β-, and γ-Synuclein Neuropathology , 2000 .

[13]  B. Giasson,et al.  Dityrosine cross-linking promotes formation of stable alpha -synuclein polymers. Implication of nitrative and oxidative stress in the pathogenesis of neurodegenerative synucleinopathies. , 2000, The Journal of biological chemistry.

[14]  F. Checler,et al.  α-Synuclein and the Parkinson's disease-related mutant Ala53Thr-α-synuclein do not undergo proteasomal degradation in HEK293 and neuronal cells , 2000, Neuroscience Letters.

[15]  J. Trojanowski,et al.  Synucleins are expressed in the majority of breast and ovarian carcinomas and in preneoplastic lesions of the ovary , 2000, Cancer.

[16]  J. Trojanowski,et al.  Synucleins Are Developmentally Expressed, and α-Synuclein Regulates the Size of the Presynaptic Vesicular Pool in Primary Hippocampal Neurons , 2000, The Journal of Neuroscience.

[17]  S. Hirai,et al.  Accumulation of NACP/α-synuclein in Lewy body disease and multiple system atrophy , 2000, Journal of neurology, neurosurgery, and psychiatry.

[18]  V Hachinski,et al.  Vascular Factors in Cognitive Impairment‐Where Are We Now? , 2000, Annals of the New York Academy of Sciences.

[19]  J. Trojanowski,et al.  A panel of epitope‐specific antibodies detects protein domains distributed throughout human α‐synuclein in lewy bodies of Parkinson's disease , 2000, Journal of neuroscience research.

[20]  Heidi Phillips,et al.  Mice Lacking α-Synuclein Display Functional Deficits in the Nigrostriatal Dopamine System , 2000, Neuron.

[21]  P. Lansbury,et al.  Acceleration of oligomerization, not fibrillization, is a shared property of both alpha-synuclein mutations linked to early-onset Parkinson's disease: implications for pathogenesis and therapy. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[22]  R. Krüger,et al.  Involvement of α-synuclein in Parkinson's disease and other neurodegenerative disorders , 2000, Journal of neural transmission.

[23]  T. Chase,et al.  Degradation of α-Synuclein by Proteasome* , 1999, The Journal of Biological Chemistry.

[24]  J Q Trojanowski,et al.  Axon pathology in Parkinson's disease and Lewy body dementia hippocampus contains alpha-, beta-, and gamma-synuclein. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[25]  Shinn-Zong Lin,et al.  Absence of G209A and G88C Mutations in the Alpha-Synuclein Gene of Parkinson’s Disease in a Chinese Population , 1999, European Neurology.

[26]  G. Billman,et al.  The Antiarrhythmic and Anticonvulsant Effects of Dietary N-3 Fatty Acids , 1999, The Journal of Membrane Biology.

[27]  E. Masliah,et al.  Role of Cytochrome c as a Stimulator of α-Synuclein Aggregation in Lewy Body Disease* , 1999, The Journal of Biological Chemistry.

[28]  Sid Gilman,et al.  Widespread Alterations of α-Synuclein in Multiple System Atrophy , 1999 .

[29]  Fran Maher,et al.  Non-Aβ Component of Alzheimer's Disease Amyloid (NAC) Revisited: NAC and α-Synuclein Are Not Associated with Aβ Amyloid , 1999 .

[30]  D. Clayton,et al.  Synucleins in synaptic plasticity and neurodegenerative disorders , 1999, Journal of neuroscience research.

[31]  A. Podtelejnikov,et al.  Endophilin I mediates synaptic vesicle formation by transfer of arachidonate to lysophosphatidic acid , 1999, Nature.

[32]  M. Citron,et al.  alpha-synuclein fibrillogenesis is nucleation-dependent. Implications for the pathogenesis of Parkinson's disease. , 1999, The Journal of biological chemistry.

[33]  J. Trojanowski,et al.  Epitope mapping of LB509, a monoclonal antibody directed against human α-synuclein , 1999, Neuroscience Letters.

[34]  S. Ryu,et al.  Selective activation of phospholipase D2 by unsaturated fatty acid , 1999, FEBS letters.

[35]  M. Citron,et al.  Both Familial Parkinson’s Disease Mutations Accelerate α-Synuclein Aggregation* , 1999, The Journal of Biological Chemistry.

[36]  J. Trojanowski,et al.  Mutant and Wild Type Human α-Synucleins Assemble into Elongated Filaments with Distinct Morphologies in Vitro * , 1999, The Journal of Biological Chemistry.

[37]  E. Masliah,et al.  Oxidative stress induces amyloid-like aggregate formation of NACP/α-synuclein in vitro , 1999 .

[38]  J. Trojanowski,et al.  Antibodies to α‐synuclein detect Lewy bodies in many Down's syndrome brains with Alzheimer's disease , 1999, Annals of neurology.

[39]  J. Liu,et al.  Stimulation of breast cancer invasion and metastasis by synuclein gamma. , 1999, Cancer research.

[40]  J. Celis,et al.  Short‐term culturing of low‐grade superficial bladder transitional cell carcinomas leads to changes in the expression levels of several proteins involved in key cellular activities , 1999, Electrophoresis.

[41]  A. Goate,et al.  Mutation, sequence analysis, and association studies of α-synuclein in Parkinson's disease , 1998, Neurology.

[42]  J. Langston,et al.  Novel α-Synuclein-Immunoreactive Proteins in Brain Samples from the Contursi Kindred, Parkinson's, and Alzheimer's Disease , 1998, Experimental Neurology.

[43]  E. Jaros,et al.  Mutation screening in exons 3 and 4 of alpha-synuclein in sporadic Parkinson's and sporadic and familial dementia with Lewy bodies cases. , 1998, Neuroreport.

[44]  R. Jakes,et al.  Effects of the mutations Ala30 to Pro and Ala53 to Thr on the physical and morphological properties of α‐synuclein protein implicated in Parkinson's disease , 1998, FEBS letters.

[45]  J Q Trojanowski,et al.  Lewy bodies contain altered alpha-synuclein in brains of many familial Alzheimer's disease patients with mutations in presenilin and amyloid precursor protein genes. , 1998, The American journal of pathology.

[46]  Peter T. Lansbury,et al.  Accelerated in vitro fibril formation by a mutant α-synuclein linked to early-onset Parkinson disease , 1998, Nature Medicine.

[47]  R. Anthony Crowther,et al.  Synthetic filaments assembled from C‐terminally truncated α‐synuclein , 1998 .

[48]  J Q Trojanowski,et al.  Glial cytoplasmic inclusions in white matter oligodendrocytes of multiple system atrophy brains contain insoluble α‐synuclein , 1998, Annals of neurology.

[49]  A. Schapira,et al.  The role of the α-synuclein gene mutation in patients with sporadic Parkinson’s disease in the United Kingdom , 1998, Journal of neurology, neurosurgery, and psychiatry.

[50]  C. Marsden,et al.  The α‐synuclein Ala53Thr mutation is not a common cause of familial Parkinson's disease: A study of 230 European cases , 1998 .

[51]  Nigel J. Cairns,et al.  Filamentous α-synuclein inclusions link multiple system atrophy with Parkinson's disease and dementia with Lewy bodies , 1998, Neuroscience Letters.

[52]  Makoto Hashimoto,et al.  Human recombinant NACP/α-synuclein is aggregated and fibrillated in vitro: Relevance for Lewy body disease , 1998, Brain Research.

[53]  E. Niki,et al.  Acrolein Is a Product of Lipid Peroxidation Reaction , 1998, The Journal of Biological Chemistry.

[54]  Hitoshi Takahashi,et al.  α-Synuclein immunoreactivity in glial cytoplasmic inclusions in multiple system atrophy , 1998, Neuroscience Letters.

[55]  David F. Clayton,et al.  The synucleins: a family of proteins involved in synaptic function, plasticity, neurodegeneration and disease , 1998, Trends in Neurosciences.

[56]  R. Crowther,et al.  α-Synuclein in filamentous inclusions of Lewy bodies from Parkinson’s disease and dementia with Lewy bodies , 1998 .

[57]  A. Jonas,et al.  Stabilization of α-Synuclein Secondary Structure upon Binding to Synthetic Membranes* , 1998, The Journal of Biological Chemistry.

[58]  B. Hyman,et al.  Nigral and Cortical Lewy Bodies and Dystrophic Nigral Neurites in Parkinson's Disease and Cortical Lewy Body Disease Contain α-synuclein Immunoreactivity , 1998, Journal of neuropathology and experimental neurology.

[59]  J Q Trojanowski,et al.  Aggregation of alpha-synuclein in Lewy bodies of sporadic Parkinson's disease and dementia with Lewy bodies. , 1998, The American journal of pathology.

[60]  A. Morris,et al.  Regulation of phospholipase D2: selective inhibition of mammalian phospholipase D isoenzymes by alpha- and beta-synucleins. , 1998, Biochemistry.

[61]  M. Farrer,et al.  Low frequency of α‐synuclein mutations in familial Parkinson's disease , 1998, Annals of neurology.

[62]  Olaf Riess,et al.  AlaSOPro mutation in the gene encoding α-synuclein in Parkinson's disease , 1998, Nature Genetics.

[63]  D. Clayton,et al.  Synelfin Regulation during the Critical Period for Song Learning in Normal and Isolated Juvenile Zebra Finches , 1997, Neurobiology of Learning and Memory.

[64]  Robert L. Nussbaum,et al.  Mutation in the α-Synuclein Gene Identified in Families with Parkinson's Disease , 1997 .

[65]  G. Xiao,et al.  Identification of a breast cancer-specific gene, BCSG1, by direct differential cDNA sequencing. , 1997, Cancer research.

[66]  David F. Clayton,et al.  Characterization of a novel protein regulated during the critical period for song learning in the zebra finch , 1995, Neuron.

[67]  P. Sastry,et al.  Lipids of nervous tissue: composition and metabolism. , 1985, Progress in lipid research.

[68]  R. D. Carlson,et al.  A simple method for the preparation of homogeneous phospholipid vesicles. , 1977, Biochemistry.

[69]  J. Folch,et al.  A simple method for the isolation and purification of total lipides from animal tissues. , 1957, The Journal of biological chemistry.